Charles Schwab Investment Management Inc. Acquires 9,955 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

Charles Schwab Investment Management Inc. raised its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) by 0.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,222,201 shares of the biopharmaceutical company’s stock after acquiring an additional 9,955 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.64% of Arbutus Biopharma worth $3,997,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Intech Investment Management LLC bought a new position in shares of Arbutus Biopharma in the 3rd quarter worth $142,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Arbutus Biopharma by 453.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 30,723 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Arbutus Biopharma during the third quarter worth about $754,000. Rockefeller Capital Management L.P. acquired a new position in shares of Arbutus Biopharma during the 3rd quarter worth about $243,000. Finally, Janus Henderson Group PLC bought a new stake in shares of Arbutus Biopharma in the 3rd quarter valued at about $234,000. Institutional investors and hedge funds own 43.79% of the company’s stock.

Arbutus Biopharma Price Performance

NASDAQ:ABUS opened at $3.35 on Thursday. The business’s 50-day simple moving average is $3.33 and its 200-day simple moving average is $3.58. Arbutus Biopharma Co. has a fifty-two week low of $2.30 and a fifty-two week high of $4.73. The stock has a market capitalization of $634.80 million, a PE ratio of -7.79 and a beta of 1.93.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. StockNews.com lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.